A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Brief description of study

The purpose of the study is to determine and evaluate the efficacy as well as safety of the combination of nivolumab plus relatlimab and PDCT vs nivolumab and PDCT in adults with untreated Stage IV or recurrent Non-small Cell Lung Cancer, as first line treatment. We want to know the safety and tolerability of the different combination of drugs. In addition, we want to compare the progression free survival for the following drug combination: ofnivolumab plus relatlimab in combination with PDCT vs nivolumab in combination with PDCT in participants with histologically confirmed IL Stage IV or recurrent NSCLC, in subgroups defined by PD-Ll expression, LAG-3 expression, FG-Ll expression.

Clinical Study Identifier: s20-01357
ClinicalTrials.gov Identifier: NCT04623775

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.